Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2011
December 1, 2011
- Acucela to Present ACU-4429 Phase 1 Data at the 10th International Symposium on Ocular Pharmacology and Therapeutics
- Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
- Ablynx Reports Positive Phase I Data for Alx-0061 in Rheumatoid Arthritis
- US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
- Cytokinetics Announces Positive Results From Phase II Clinical Trial Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
- Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study
- Results of First Whole-Genome Sequencing Clinical Trial for Triple-Negative Breast Cancer Patients Will Be Presented at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
- Santarus Announces Presentation of New Open-Label UCERIS (Budesonide) Data at the Crohn's and Colitis Foundation Clinical & Research Conference
December 2, 2011
- Oncolytics Biotech Inc. Announces Phase 2 Clinical Trial of REOLYSIN in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint
- BioInvent: BI-505 Data at American Society of Hematology
- STEDESA Clinical Data Presented at 2011 American Epilepsy Society Annual Meeting
- Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
December 5, 2011
- ARIAD Announces Investor Meeting and Webcast at American Society of Hematology Meeting
- Emergent BioSolutions Announces Acceptance of Four TRU-016 Abstracts for Presentation at 2011 American Society of Hematology Annual Meeting
- Two Year Results of Phase 3 Studies with Eylea (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
- Five Presentations at American Epilepsy Society Annual Meeting Highlight Data on Lundbeck's ONFI? (clobazam)
- Gilead's Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study
- XenoPort Announces XP21279 Phase 2 Clinical Trial Results in Patients With Advanced Parkinson's Disease
- EnVivo Pharmaceuticals Presents Positive Comprehensive Phase 2b Study Results in Schizophrenia at American College of Neuropsychopharmacology Annual Meeting
- Long-term Use of Antiepileptic Drug Vimpat (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
- Sequenta Presents Key Data at the 2011 American Society of Hematology Annual Meeting
- U-M Researchers Use Stem Cells to Gain New Insight into Severe Childhood Form of Epilepsy
December 6, 2011
- Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C
- Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
- Acacia Pharma Announces Positive Results From Phase Iia Cancer Cachexia Study
- Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels and Triglycerides
- Zealand Pharma announces new results on lixisenatide (Lyxumia®1)) for Type 2 diabetes presented by Sanofi at the 21st World Diabetes Congress
- Positive results reported by Sanofi for once-daily lixisenatide (Lyxumia 1)) in combination with Lantus? (insulin glargine) in Type 2 diabetes
- Long-term use of antiepileptic drug Vimpat® (lacosamide) reduced seizure frequency and severity and improved health-related quality of life measures
- Pooled Analysis: Fewer Major Adverse Cardiovascular Events in Type 2 Diabetes Patients Treated with MSD?s JANUVIA (sitagliptin)
- BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain
- ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze(R) (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
- Synta Announces Publication of Ganetespib Results in Molecular Cancer Therapeutics
- Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients (6 December 2011)
- Study shows promising multiple sclerosis treatment targets immune cells to increase neuroprotection
December 7, 2011
- Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 into Clinical Trials for Adult ADHD
- Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism
- Androgen Deprivation Therapy for Treatment of Prostate Cancer Not Associated With Increased Risk of Cardiovascular Death
- PolyMedix Announces Encouraging Interim Results from Multinational Phase 2 Clinical Trial with PMX-30063 Defensin-Mimetic Antibiotic
- Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism
- Italian Laboratory Expands ProtoKinetix' Market for AAGP
- Leading Investigator to Present Clinical Data on Generex Oral-lyn at International Diabetes Federation Meetings in Dubai
- Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
- Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
- From the Outside In: Mayo Clinic Collaboration Finds Multiple Sclerosis Often Starts in Brain's Outer Layers
- MuGard Advocate Interviewed on ABC Tampa News at Noon
December 8, 2011
- Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
- Shire Reports Positive Phase II Results for Investigative Use of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII)
- New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment
- Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer
- Ganetespib Shows Clinical Activity in HER2+ and Triple Negative Metastatic Breast Cancer
- Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
- Exelixis' Cabozantinib Shows Encouraging Clinical Activity in Patients With Metastatic Breast Cancer
- The New England Journal of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness
- The International Myeloma Foundation Says 10 Years after Introduction of the Novel Therapies Survival, Quality of Life, and Treatment Options Significantly Improve
- New Data Confirms Novartis Drug Afinitor Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
- Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
- Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
- SEQUEL Trial Results for Qnexa Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
- Bionovo Announces the Publication of its Tissue Selective Estrogen Receptor Modulators for Postmenopausal Obesity
- BioChemics Announces Positive Phase 2 Data for a Novel Transdermal Ibuprofen Drug Formulation Developed to Treat Osteoarthritis
- Genome Sequencing Reveals Previously Unreported Genetic Changes in Triple Negative Breast Tumors
- Metabolon Study Reveals Mechanisms of High Dosage Pentamethyl-6-Chromanol (PMCol) Toxicity in Liver Damage and Dysfunction
December 9, 2011
- Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011
- Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium
- OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
- MediGene Presents Overall Survival Data from a Phase II Trial of EndoTAG-1 in Triple-Negative Breast Cancer (TNBC)
- GSK Presents Phase Lll Data for Lapatinib at San Antonio Breast Cancer Symposium
- Blood Pressure Medicines Reduce Stroke Risk in People With Prehypertension
- Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV
- Chronic pain in children and adolescents becoming more common
- Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
- Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 American Society of Hematology Annual Meeting
December 12, 2011
- AMAG Pharmaceuticals Announces Preliminary Data Regarding the Safety and Efficacy of a Single Infusion of 1020 mg Ferumoxytol (Feraheme) in Patients with Iron Deficiency Anemia
- Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
- S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
- New Data Confirm Hemolysis as Predictor of Thromboembolism and Early Death in Patients with PNH and Demonstrate Need To Test High-Risk Patients for PNH
- Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting
- Plexxikon Advances Novel Targeted Treatment PLX3397 in Blood Cancer
- Cornerstone Pharmaceuticals' Cancer Metabolism Inhibitor, CPI-613, Showing Promise in Phase I Trial for Acute Myeloid Leukemia
- Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS (Brentuximab Vedotin) at ASH Annual Meeting
- Micromet's Blinatumomab Produces High Rate of Durable Hematologic Complete Remissions in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
- Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients
- Celator Pharmaceuticals and the Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting
- Pharmacyclics Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology (ASH) Annual Meeting
- Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
- Avila Therapeutics Presents Data on AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 ASH Annual Meeting
- Second Self Medicated Medical Cannabis Cancer Patient Reports Cannabis Science Brand Extracts Killing Cancer Cells
- New Study Shows No Difference in Survival between Bone Marrow and Peripheral Blood in Patients Receiving a Transplant from a Donor Unrelated to the Patient
- Overall Survival Benefit with VELCADE Based Therapy in Previously Untreated Multiple Myeloma Patients Maintained After Five Year Follow-Up
- ?China Forum II? to Lead off 5th Annual OneMedForum
December 13, 2011
- Trophos announces results of phase III study of olesoxime in Amyotrophic Lateral Sclerosis
- Cylene First-in-Class Agents Show Promise in High Risk Blood Cancers at ASH
- Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
- Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
- Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna(R) Compared to Gleevec(R)
- Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
- Actelion provides an update on the strategic agreement with Trophos S.A.
- Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting
- Study Does Not Find Increased Risk of Serious Cardiovascular Events Among Young and Middle-Aged Adults Who Use ADHD Medications
- Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
December 14, 2011
- Meta-analysis of Five Clinical Trials including Columbia Laboratories' PREGNANT Study Published in American Journal of Obstetrics and Gynecology
- Bisphosphonate Antiresorptive Agent, Ibandronate Sodium Hydrate Injection, Demonstrates Efficacy in Osteoporosis in Phase II/III Trial
- Presentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma
- Aestus Therapeutics Reports Positive Results in Phase II Neuropathic Pain Trial for Treatment of Post-Herpetic Neuralgia
- Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate(R) (Romiplostim)
- Metabolon Extends Biochemical Understanding of Amyotrophic Lateral Sclerosis (ALS)
- FDA Regulatory Seminars for Life Science Industry Professionals
- Major New International Study Shows the Effectiveness and Safety of Vaginal Progesterone in the Prevention of Preterm Birth
- Complete Agenda Announced for Pharma/Biotech Accounting and Reporting Congress
- Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
- BioSante Pharmaceuticals Announces Results from LibiGel Efficacy Trials
December 15, 2011
- BiovaxID Lymphoma Vaccine is Featured in Articles Published in Newsweek and Genetic Engineering & Biotechnology News
- Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections
- Successful Completion of Hatchtech's Phase 2b Clinical Trial in Head Lice
- DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators
- West Palm Beach, FL to Host 8th Annual World Stem Cell Summit December 3-5, 2012
- Discover how much CROs are used at the ?2nd Annual State of Clinical Development Cost Conference' Sponsored by TTC
- Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy
- Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs)
- Abbott to Present at J.P. Morgan Healthcare Conference
- Usage of Zyvox Has Flattened or Declined in the Major European Markets While Uptake of Cubicin and Tygacil Has Climbed Year over Year since 2007
- UBM Medica's CancerNetwork Provides Key Coverage of the 2011 ASH Meeting in San Diego
December 16, 2011
- Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome
- Novartis Drug Gilenya Showed Positive Clinical Outcomes for Relapsing-Remitting MS Patients in Third Large Phase III Clinical Trial
- SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
- Advaxis Reports Preliminary Data from ADXS-HPV Phase 2 Trial in Patients with Recurrent/Refractory Cervical Cancer at AACR India
- Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting
- Novartis pivotal study of Exjade shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
- Novartis pivotal study of Exjade shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
December 19, 2011
- Pulmatrix Presents Data on iSPERSE for Inhaled Combination Drug Therapies, Including Triple Drug Combinations
- Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL Pivotal Trial Published in Diseases of the Colon & Rectum
- Yissum Introduces a Novel Technology for Manufacturing an Anti-Malaria Drug in Tobacco
- SFDA China Visits DIA Global Headquarters to Discuss the Future of Global Medical Product Development
- Selexys Pharmaceuticals Completes Phase I Clinical Study for Sickle Cell Drug
- Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
- The Kenneth Rainin Foundation Announces 2012 Innovations Symposium - New Insights In Human Evolution and IBD
- WIN Consortium Announces the Scientific Program of WIN 2012 Symposium Where Leaders from Academia, Industry and Regulatory Agencies Will Debate Ways to Improve Efficacy of Cancer Therapeutics in Individual Patients
- Catalyst Announces Publication of CPP-115 Scientific Paper in Journal of Medicinal Chemistry
- Landmark Publication Endorses Prana`s Strategy
- Targeting EETs to Treat Cardiovascular Disease May Prove a Double-Edged Sword
- Oxford BioMedica Announces Interim Update on ProSavin Phase I/II Study in Parkinson's Disease
- Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE in the Treatment of Lymphoma
December 20, 2011
- Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
- AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder
- Clinuvel announces positive results from pivotal European Phase III study: endpoints demonstrate clinically relevant treatment effect of afamelanotide
- Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
- inThought Report Says New Wave of Cardiology Drugs to Be Big Boon
- BiovaxID Lymphoma Vaccine is Featured in Article Published in Yale Journal of Biology and Medicine
- Can Innovation Save Healthcare? CEOs From Around The World to Address This Challenge at 'The Global Leaders Healthcare Forum' in San Francisco January 10
- BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study
December 21, 2011
- Celldex Completes Accrual of CDX-011 Phase 2b ?EMERGE? Study in Advanced Breast Cancer
- Research Reveals Possible Treatment for Autism-related Angelman Syndrome
- Healthcare, Biotech and Pharmaceutical Leaders to Meet With Investors in Search of Breakthrough Business Solutions at 'The Global Leaders Healthcare Forum' in San Francisco January 10
December 22, 2011
- Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms
- Nuvilex Associate's Patent Expansion Sets Stage for Treatment of HIV, Ebola, and SARS Virus
- VIVUS Reports Topline Findings From FORTRESS
- Increase your Knowledge on Site Start-Up Costs at the ?2nd Annual State of Clinical Development Cost Conference'
- BASF, GlaxoSmithKline, Merck and Novartis Among Companies to Schedule Partnering Sessions at CED Life Science Conference 2012
- Celldex Completes Accrual of CDX-011 Phase 2b ?EMERGE? Study in Advanced Breast Cancer
- Chelsea Therapeutics Reports Topline Results From Phase II Trial of Droxidopa in Fibromyalgia
- Noven Announces Phase 3 Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms
- BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed
December 25, 2011
December 27, 2011
- China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair
- 22nd Century Group Announces Initial Results of Smoking Cessation Trial
- TPI Presents at the 2nd Annual OneMed China Forum on January 9th, 2012 in San Francisco
- Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
- MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference
- Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise in Open-Label Extension Study
